Over the past several years, cell therapy has seen explosive growth in the number and variety of applications and disease targets under exploration for commercialization, a trend that is unlikely to slow. The diversity of manufacturing strategies and technology to support this growth has also evolved, albeit more slowly. Cell therapy manufacturers now face a wider range of decisions when it comes to implementing automated solutions in their process. And committing to the wrong manufacturing technology early in commercialization can mean expensive, risky delays with late process transfers and comparability studies.In this webinar, we will discuss the cell expansion step of the manufacturing cycle, unpacking critical elements and trends to consider when choosing when and how to automate this lengthy, labor-intensive process: